Search

Displaying results 3371 - 3380 of 8697 in total
  1. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). … for NASH[L1662].

  2. Drug

    Curcuma xanthorrhiza oil

    go.drugbank.com/drugs/DB11265
    ApprovedNutraceutical

    For centuries, _Curcuma xanthorrhiza_ oil has been used as a traditional medicine due to its antibacterial, antispasmodic, antioxidative, antitumor, anti-inflammatory and protective effects [A33160]. … _Curcuma xanthorrhiza_ oil is found as an active ingredient in cosmetic and hygienic products, and marketing of products containing _Curcuma xanthorrhiza_ oil is authorized in some European countries including

  3. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting … While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects.

    Categories: Cannabinoid Receptor Agonists, P-glycoprotein inhibitors
  4. Drug

    PF-04634817

    go.drugbank.com/drugs/DB14955
    Investigational

    PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).

  5. Drug

    PF-07038124

    go.drugbank.com/drugs/DB19143
    Investigational

    PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).

  6. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    [A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD. … as well as the need for surgical revascularization or angioplasty following a heart attack.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Cytochrome P-450 Substrates
  7. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L46616] In May 2023, sotagliflozin was approved by the FDA to reduce the risk of cardiovascular death and heart failure in patients with high risk factors.[] … [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019.

    Categories: Anti-Acne Preparations for Topical Use, Retinoids for Topical Use in Acne
  9. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper.

  10. Drug

    1,2-dichlorobenzene

    go.drugbank.com/drugs/DB13963
    ApprovedWithdrawn

    This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as … an insecticide and as an agent to remove carbon-based contamination from metal.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates